Alcon, CH0432492467

Systane Complete by Alcon - dry eye relief with lipid layer support

Published on 07/08/2026 at 14:55 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS

Systane Complete delivers targeted dry eye relief by stabilizing the tear film’s lipid layer and is positioned as an all-in-one lubricant eye drop in Alcon’s portfolio. This product is driving the price of Alcon Inc. stock (ISIN CH0432492467).

Alcon, CH0432492467, Illustration mit AI erstellt.
Alcon, CH0432492467, Illustration mit AI erstellt.

Systane Complete lands as a small, cool drop on the eye, then spreads into a thin film that feels more like a soft contact lens than liquid. The first time, as product manager Dr. Ranjani Varadarajan demonstrates it in the lab, the microemulsion texture is immediately noticeable.

Microemulsion for the whole tear film

Alcon Inc. places Systane Complete in its dry eye range as an "all-in-one" lubricant drop designed to address all major tear film layers – aqueous, lipid and mucin – rather than just adding moisture. Official product information by Alcon The formulation uses a nano-sized oil-in-water microemulsion to help restore and stabilize the lipid layer, reducing evaporation of the natural tear film.

Unlike traditional, purely aqueous artificial tears, Systane Complete carries propylene glycol as the active lubricant, combined with hydroxypropyl guar, mineral oils and phospholipids that form the microemulsion structure. Detailed patient information leaflet According to Alcon’s materials, the guar-based gel network interacts with the ocular surface, increasing residence time and creating a more stable pseudo-gel upon contact with the tear film.

Dig deeper & contextualize

Alcon Inc. and its dry eye franchise

Dry eye therapies like Systane Complete contribute to Alcon Inc.’s broader ophthalmic portfolio alongside surgical and vision care products.

Positioning within the Systane family

Within Alcon’s Systane brand architecture, Systane Complete sits alongside variants such as Systane Ultra, Systane Hydration and Systane Gel Drops, but is explicitly marketed as covering both evaporative and aqueous-deficient dry eye. It targets patients whose symptoms include burning, stinging, or a gritty sensation, often tied to meibomian gland dysfunction.

CEO David Endicott repeatedly stresses in public presentations that dry eye is a structural growth driver for Alcon, fuelled by aging demographics and screen-heavy lifestyles, and Systane is one of the group’s anchor consumer brands. Alcon investor presentation with Systane brand references Portfolio moves like Systane Complete are therefore less about quick novelty and more about rounding out coverage of distinct patient profiles.

Use, comfort and dosing

From the user’s perspective, Systane Complete comes as a multi-dose 10 ml bottle in many markets, including Germany, and is classified as a lubricant eye drop used up to several times per day as needed. Systane Complete product details for Germany The fluid is slightly milky due to the microemulsion and feels more substantial on the eye than clear saline tears, but remains free-flowing, not a gel.

Instructions typically advise users to shake the bottle before use, place 1 or 2 drops into the affected eye as required, and wait a short moment for vision to clear as the emulsion spreads and integrates with the tear film. This brief moment of blurred vision is a practical detail that ophthalmologists often mention when counselling patients in clinic rooms that still smell faintly of disinfectant.

Formulation and preservatives

Systane Complete is a preservative-containing drop in most widely documented formulations, using POLYQUAD (polyquaternium-1) at low concentration, a quaternary ammonium compound designed to be gentler than benzalkonium chloride on corneal epithelial cells. For many patients with mild to moderate dry eye, this trade-off between shelf life and tolerability is acceptable, but highly sensitive or post-surgical eyes may be steered towards preservative-free options.

To mitigate surface stress, the product leans on its hydroxypropyl guar and borate buffer system, which has a long track record in Systane formulations. The guar component forms a pseudo-gel matrix on the ocular surface when exposed to tear film ions, potentially improving comfort and reducing mechanical friction from eyelid movements. Clinical review of Systane formulations

Clinical data and efficacy signals

Peer-reviewed data on Systane Complete remains more limited than decades-old artificial tear solutions, but some clinical evaluations report improved tear breakup time and symptom scores versus baseline in patients with evaporative dry eye when using the microemulsion approach. These studies typically track outcomes via questionnaires such as the Ocular Surface Disease Index and objective measurements like non-invasive tear breakup time.

Mechanistically, the added lipid components aim to address an increasingly recognised cause of complaints: meibomian gland dysfunction leading to an unstable lipid layer and accelerated evaporation. Alcon’s own materials describe Systane Complete as suitable when patients complain about fluctuating vision and discomfort that worsens across the day, a pattern often associated with evaporation rather than insufficient tear production alone.

Market position and competition

On store shelves, Systane Complete typically competes with other multi-dose, oil-containing lubricants from players such as Bausch + Lomb and Johnson & Johnson Vision, as well as with pharmacy brands and private labels. Pricing in Germany, for example, tends to place Systane Complete in the branded, mid-to-upper segment of lubricant drops rather than the low-budget saline tier.

Industry observers track dry eye categories as recurring revenue pools, since patients often use drops chronically. Management commentary from David Endicott and CFO Tim Stonesifer regularly underscores that consumer eye care products, including Systane, deliver attractive margins compared with commodity generics, though innovation pressure remains because users quickly notice texture and comfort differences among drops. Alcon earnings materials on vision care

Accessibility and indications

In Germany and many other European markets, Systane Complete is typically sold over the counter in pharmacies and sometimes optician practices, not as a prescription drug. Labeling emphasises symptomatic relief of dry eye and ocular surface discomfort rather than treatment of underlying inflammatory diseases, and users are told to seek medical advice if symptoms persist or worsen.

For contact lens wearers, Alcon usually directs users towards specific Systane variants indicated for lens compatibility, while Systane Complete is more often framed as a drop for non-lens wearers or for use before and after lens periods. That distinction matters because oil-containing drops can interact with lens surfaces, and the cool, slightly viscous feel that helps bare corneas may not translate well under a lens.

Alcon stock context

From an equity angle, Systane Complete represents another brick in Alcon’s broader strategy to grow consumer eye care revenues alongside its surgical portfolio. Dry eye demand and branded OTC products help smooth revenue cycles compared with one-off surgical equipment sales, and provide a recognisable brand touchpoint at retail level for a company still mainly associated with ophthalmologists.

On the SIX Swiss Exchange, the Alcon Inc. share (ISIN CH0432492467) trades in Swiss francs and reflects, among other factors, expectations about sustained demand in segments such as Systane lubricant drops and other recurring-consumption eye care products. Alcon Inc. listing information on SIX Swiss Exchange

Key facts on Systane Complete

  • Product: Systane Complete
  • Manufacturer: Alcon Inc.
  • Category: Accessory / Spare part (dry eye lubricant eye drops)
  • Market launch: Around 2018 in major markets such as the US and Europe, following Alcon’s expansion of the Systane family.
  • MSRP / Price: In Germany, typical retail prices for a 10 ml bottle range roughly around 12-15 EUR, varying by pharmacy and promotions.
  • Availability: Over-the-counter in pharmacies and some optician practices in markets including Germany; availability may vary by country.
  • Target group: Adults with evaporative or mixed-mechanism dry eye symptoms, including burning, stinging and gritty sensations, often linked to meibomian gland dysfunction.
  • Highlight / USP: Microemulsion technology designed to stabilise the tear film lipid layer while providing lubricant relief across multiple tear film components.

Follow Systane Complete across platforms

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | CH0432492467 | ALCON | boerse | 69723824 | bgmi